Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.06
-0.1400-2.26%
Post-market: 6.250.1900+3.14%19:08 EDT
Volume:1.05M
Turnover:6.45M
Market Cap:524.64M
PE:-2.90
High:6.26
Open:6.19
Low:6.01
Close:6.20
Loading ...

Kura Oncology Announces Positive Phase 1a/1b Trial Results

TIPRANKS
·
3 hours ago

Kura Oncology Inc. Unveils Presentation on Ziftomenib for AML Treatment and Development Plans

Reuters
·
3 hours ago

Kura Oncology (KURA) Gets a Buy from TD Cowen

TIPRANKS
·
13 Jun

Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology

TIPRANKS
·
13 Jun

Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia

MT Newswires Live
·
12 Jun

Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
10 Jun

Kura Oncology Stockholders Approve Equity Plan Amendment

TIPRANKS
·
07 Jun

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
06 Jun

BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
06 Jun

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Jun

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

TIPRANKS
·
04 Jun

Kura Oncology (KURA) Receives a Buy from Leerink Partners

TIPRANKS
·
03 Jun

Cantor Fitzgerald Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
03 Jun

Kura Oncology data overhangs receding, says BofA

TIPRANKS
·
03 Jun

Kura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth

TIPRANKS
·
03 Jun

Kura Oncology says ‘positive’ results from KOMET-001 Phase 2 trial of ziftomenib

TIPRANKS
·
03 Jun

Kura Oncology Unveils Presentation on Transformative Therapies for Acute Myeloid Leukemia at ASCO Event

Reuters
·
03 Jun

BRIEF-Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data

Reuters
·
03 Jun

Kura Oncology Inc: FDA Pdufa Target Action Date of November 30 for Ziftomenib

THOMSON REUTERS
·
03 Jun

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

GlobeNewswire
·
03 Jun